Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
6.320
-0.050 (-0.78%)
Streaming Delayed Price
Updated: 12:12 PM EDT, Apr 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
456,891
Open
6.310
Bid (Size)
6.310 (900)
Ask (Size)
6.320 (800)
Prev. Close
6.370
Today's Range
6.185 - 6.345
52wk Range
3.950 - 10.08
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
↗
March 02, 2026
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
Performance
YTD
-14.0%
-14.0%
1 Month
+16.2%
+16.2%
3 Month
-17.0%
-17.0%
6 Month
-32.3%
-32.3%
1 Year
+57.2%
+57.2%
More News
Read More
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook
↗
March 02, 2026
Via
Chartmill
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
March 02, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
February 26, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
February 17, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
January 08, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 02, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
↗
December 31, 2025
Via
The Motley Fool
The market is filled with gapping stocks in Wednesday's session.
↗
December 31, 2025
Via
Chartmill
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
December 01, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript
↗
November 06, 2025
Via
The Motley Fool
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates
↗
November 06, 2025
Via
Chartmill
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
November 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
October 23, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
August 25, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris (XERS) Q2 Revenue Jumps 49%
↗
August 07, 2025
Via
The Motley Fool
Traders are paying attention to the gapping stocks in Thursday's session.
↗
August 07, 2025
Via
Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance
↗
August 07, 2025
Via
Chartmill
Topics
Earnings
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
August 07, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria
↗
July 07, 2025
Via
Chartmill
Frequently Asked Questions
Is Xeris Biopharma Holdings, Inc. - Common Stock publicly traded?
Yes, Xeris Biopharma Holdings, Inc. - Common Stock is publicly traded.
What exchange does Xeris Biopharma Holdings, Inc. - Common Stock trade on?
Xeris Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock?
The ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock is XERS on the Nasdaq Stock Market
What is the current price of Xeris Biopharma Holdings, Inc. - Common Stock?
The current price of Xeris Biopharma Holdings, Inc. - Common Stock is 6.320
When was Xeris Biopharma Holdings, Inc. - Common Stock last traded?
The last trade of Xeris Biopharma Holdings, Inc. - Common Stock was at 04/20/26 12:12 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
